Lattise: An FDA Approved Eyelash Treatment

An FDA clinical trial of participants using LATISSE® (bimatoprost ophthalmic solution) 0.03%, and documented their progress throughout the 16-week treatment period. The results were more than eye-catching: 78% of participants experienced a significant increase in overall eyelash prominence (including elements of length, fullness, and darkness) at week 16. The following case studies capture these images. These are real women with real results. Their lashes have not been retouched.

LATISSE® solution is a prescription treatment for hypotrichosis used to grow eyelashes, making them longer, thicker and darker.
Eyelash hypotrichosis is another name for having inadequate or not enough eyelashes.
Get ready for an innovation in lashes.
LATISSE® (bimatoprost ophthalmic solution) 0.03% is the first and only prescription treatment approved by the FDA for inadequate or not having enough eyelashes, growing them longer, fuller and darker.
LATISSE® works effectively.
LATISSE® makes lash growth possible because of its active ingredient: bimatoprost. Although the precise mechanism of action is not known, research suggests that the growth of eyelashes occurs by increasing the percent of hairs in, and the duration of, the anagen (or growth) phase. Lashes can grow longer, thicker and darker because bimatoprost can also prolong this growth phase.
Clinically proven results you can see over time.
LATISSE® is FDA approved and effective. It’s a once-a-day treatment you apply topically to the base of your upper eyelashes. Patients in a clinical trial saw results in as few as 8 weeks with full results after 12 to 16 weeks.
It’s an innovation backed by research.
While LATISSE® is a treatment for inadequate or not enough eyelashes, it was developed through years of research by Allergan, a pharmaceutical leader with over 60 years of expertise in prescription eye care products.